STELLA PHARMA CORPORATION [4888.T]
TOKYO, May 14 (Pulse News Wire) – Stella Pharma Corporation (4888.T) corrected its previously issued earnings forecast due to an error identified in the initial report. The correction pertains to discrepancies between the forecast made on October 14, 2025, and the actual performance figures for the fiscal year ending March 31, 2026.
According to the revised data, the company's per-share metrics for the fiscal year ended March 31, 2026, show significant adjustments compared to the previous estimates: | Metric | Previous Estimate (October 14) | Actual Performance | |-----------------|-------------------------------|--------------------| | Revenue | ¥377 million | ¥323 million | | Operating Profit | ¥--¥922 million | ¥--¥748 million | | Ordinary Profit | ¥--¥908 million | ¥--¥778 million | | Net Profit | ¥--¥911 million | ¥--¥780 million | The changes reflect a decrease in revenue expectations and adjustments in profit margins. Specifically, the net profit per share was revised downward from ¥--¥26.8 million to ¥--¥22.9 million, marking a difference of ¥3.9 million.
Additionally, the operating profit saw a reduction from ¥__NUM_1__ to ¥__NUM_6__, while ordinary profit decreased from ¥__NUM_2__ to ¥__NUM_7__. For comparison, the company’s performance in the prior fiscal year (ending March 31, 2025) showed revenues of ¥961 million and a lower net profit of ¥--¥4.2 million per share.
🟢 Confidence: High AI-translated content.